Curcio Manuela, Diaz-Gomez Luis, Cirillo Giuseppe, Nicoletta Fiore Pasquale, Leggio Antonella, Iemma Francesca
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma Group, Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Pharmaceutics. 2021 Feb 26;13(3):304. doi: 10.3390/pharmaceutics13030304.
Drug targeting of tumor cells is one of the great challenges in cancer therapy; nanoparticles based on natural polymers represent valuable tools to achieve this aim. The ability to respond to environmental signals from the pathological site (e.g., altered redox potential), together with the specific interaction with membrane receptors overexpressed on cancer cells membrane (e.g., CD44 receptors), represent the main features of actively targeted nanoparticles. In this work, redox-responsive micelle-like nanoparticles were prepared by self-assembling of a hyaluronic acid-human serum albumin conjugate containing cystamine moieties acting as a functional spacer. The conjugation procedure consisted of a reductive amination step of hyaluronic acid followed by condensation with albumin. After self-assembling, nanoparticles with a mean size of 70 nm and able to be destabilized in reducing media were obtained. Doxorubicin-loaded nanoparticles modulated drug release rate in response to different redox conditions. Finally, the viability and uptake experiments on healthy (BALB-3T3) and metastatic cancer (MDA-MB-231) cells proved the potential applicability of the proposed system as a drug vector in cancer therapy.
药物靶向肿瘤细胞是癌症治疗中的重大挑战之一;基于天然聚合物的纳米颗粒是实现这一目标的宝贵工具。响应来自病理部位的环境信号(例如,氧化还原电位改变)的能力,以及与癌细胞膜上过度表达的膜受体(例如,CD44受体)的特异性相互作用,是主动靶向纳米颗粒的主要特征。在这项工作中,通过自组装含有胱胺部分作为功能间隔基的透明质酸-人血清白蛋白缀合物,制备了氧化还原响应性胶束状纳米颗粒。缀合过程包括透明质酸的还原胺化步骤,然后与白蛋白缩合。自组装后,获得了平均尺寸为70nm且能够在还原介质中不稳定的纳米颗粒。负载阿霉素的纳米颗粒响应不同的氧化还原条件调节药物释放速率。最后,对健康(BALB-3T3)和转移性癌症(MDA-MB-231)细胞的活力和摄取实验证明了所提出的系统作为癌症治疗中的药物载体的潜在适用性。